Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight

被引：154

作者：

LeBlanc, A. ^{[1
]}

Matsumoto, T. ^{[2
]}

Jones, J. ^{[3
]}

Shapiro, J. ^{[4
]}

Lang, T. ^{[5
]}

Shackelford, L. ^{[6
]}

Smith, S. M. ^{[6
]}

Evans, H. ^{[7
]}

Spector, E. ^{[7
]}

Ploutz-Snyder, R. ^{[1
]}

Sibonga, J. ^{[6
]}

Keyak, J. ^{[8
]}

Nakamura, T. ^{[9
]}

Kohri, K. ^{[10
]}

Ohshima, H. ^{[11
]}

机构：

[1] Univ Space Res Assoc, Houston, TX 77058 USA

[2] Univ Tokushima, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan

[3] Baylor Coll Med, Ctr Space Med, Houston, TX 77030 USA

[4] Kennedy Krieger Inst, Baltimore, MD 21205 USA

[5] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA

[6] NASA, Lyndon B Johnson Space Ctr, Human & Adaptat Countermeasure Div, Houston, TX 77058 USA

[7] Wyle, Houston, TX 77058 USA

[8] Univ Calif Irvine, Dept Radiol Sci, Irvine, CA 92697 USA

[9] Univ Occupat & Environm, Dept Orthoped Surg, Kitakyushu, Fukuoka, Japan

[10] Nagoya City Univ, Dept Nephrol, Nagoya, Aichi, Japan

[11] Japan Aerosp Explorat Agcy, Tsukuba, Ibaraki, Japan

来源：

OSTEOPOROSIS INTERNATIONAL | 2013年 / 24卷 / 07期

关键词：

Bisphosphonates; Bone loss; Computed bone strength; Exercise; QCT; Spaceflight; PROXIMAL FEMORAL STRENGTH; RENAL STONE FORMATION; TERM BED REST; SPACE-FLIGHT; RESISTIVE EXERCISE; FEMUR FRACTURES; BODY SCANS; OSTEONECROSIS; ASTRONAUTS; PRECISION;

D O I：

10.1007/s00198-012-2243-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.

引用

页码：2105 / 2114

页数：10

共 41 条

[1] Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures [J].